
At the center of the debate are the growing number of manufacturer demands for claims data as a condition of 340B pricing.
Pharmacogenetic testing, contraceptives, and more!
about 7 years ago
Reaching a New Generation of Consumersabout 7 years ago
New Drug Review: Vraylar for Bipolar I Disorderabout 7 years ago
AI in the Pharmacyabout 7 years ago
Zolgensma: The $2.1 Million Drugabout 7 years ago
Physician Dispensing and the Opioid Crisisabout 7 years ago
Psychotropics for Childrenabout 7 years ago
Improving the Customer Experienceabout 7 years ago
Birth Control Services Help Attract and Keep Patientsabout 7 years ago
Prevalence and Prevention of Sexual Harassment in the Pharmacyabout 7 years ago
Opinion: Clinician Burnout is Everyone's Problem





